Low Doses of Feiba Cut Risk of Relapse After Acute Bleeding Events in Acquired Hemophilia A, Study Says - Hemophilia News Today

Low Doses of Feiba Cut Risk of Relapse After Acute Bleeding Events in Acquired Hemophilia A, Study Says  Hemophilia News Today

Low doses of Feiba (aPCC) after acute bleeding events help reduce the risk of relapse in patients with acquired hemophilia A, according to a study.